Ed Mathers Mathers
Director/Board Member bij SYNLOGIC, INC.
Vermogen: 250 057 $ op 31-03-2024
Profiel
Mr. Edward T.
Mathers is an Independent Director at Affinia Therapeutics, Inc., an Independent Director at Reneo Pharmaceuticals, Inc., an Independent Director at Trevi Therapeutics, Inc., an Independent Director at Inozyme Pharma, Inc., an Independent Director at Senti Biosciences, Inc., a Lead Independent Director at Rhythm Pharmaceuticals, Inc., an Independent Director at Synlogic, Inc., a General Partner at New Enterprise Associates, Inc., a Partner at NEA Management Co. LLC and a Member at North Carolina State University College of Sciences Foundation.
He is on the Board of Directors at Affinia Therapeutics, Inc., Reneo Pharmaceuticals, Inc., Trevi Therapeutics, Inc., Inozyme Pharma, Inc., Senti Sub I, Inc., Senti Biosciences, Inc., Rhythm Pharmaceuticals, Inc., Synlogic, Inc., Code Biotherapeutics, Inc., Envisia Therapeutics, Inc., Inversago Pharma, Inc., Lumos Pharma Sub, Inc., MBX Biosciences, Inc., Shape Therapeutics, Inc., Sorriso Pharmaceuticals, Inc., SpliceBio SL and Synlogic Operating Co., Inc. Mr. Mathers was previously employed as an Independent Director by Mirum Pharmaceuticals, Inc., an Independent Director by Akouos, Inc.,
Bekende belangen in openbare bedrijven
Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
---|---|---|---|---|
21-06-2023 | 5 771 ( 0.01% ) | 250 057 $ | 31-03-2024 | |
06-06-2023 | 0 ( -.--% ) | - $ | 31-03-2024 | |
INOZYME PHARMA, INC.
-.--% | 13-06-2023 | 0 ( -.--% ) | - $ | 31-03-2024 |
TREVI THERAPEUTICS, INC.
-.--% | 28-06-2023 | 0 ( -.--% ) | - $ | 31-03-2024 |
SYNLOGIC INC
-.--% | 18-08-2023 | 0 ( -.--% ) | - $ | 31-03-2024 |
OBSEVA SA
-.--% | 24-03-2023 | 0 ( -.--% ) | - $ | 31-03-2024 |
SENTI BIOSCIENCES, INC.
-.--% | 16-06-2023 | 0 ( -.--% ) | - $ | 31-03-2024 |
Actieve functies van Ed Mathers Mathers
Bedrijven | Functie | Begin |
---|---|---|
RHYTHM PHARMACEUTICALS, INC. | Director/Board Member | 21-03-2013 |
SYNLOGIC, INC. | Director/Board Member | 01-10-2012 |
INOZYME PHARMA, INC. | Director/Board Member | 01-01-2017 |
RENEO PHARMACEUTICALS, INC. | Director/Board Member | 01-12-2017 |
TREVI THERAPEUTICS, INC. | Director/Board Member | 01-07-2017 |
SENTI BIOSCIENCES, INC. | Director/Board Member | 01-07-2016 |
Senti Sub I, Inc.
Senti Sub I, Inc. BiotechnologyHealth Technology Senti Biosciences, Inc. develops novel therapeutics. It specializes in thetic biology, gene therapy and cell therapy. The company was founded by Timothy K. Lu, Wilson Wong, James J. Collins and Philip Lee in 2016 and is headquartered in South San Francisco, CA. | Director/Board Member | 01-07-2016 |
North Carolina State University College of Sciences Foundation | Corporate Officer/Principal | - |
Shape Therapeutics, Inc.
Shape Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Shape Therapeutics, Inc. operates as a biotechnology firm. It offers genome medicine. The company was founded by Francois Vigneault and John D. Suliman in 2018 and is headquartered in Seattle, WA. | Director/Board Member | - |
░░░░ ░░░░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - |
░░░░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
Eerdere bekende functies van Ed Mathers Mathers
Bedrijven | Functie | Einde |
---|---|---|
░░░░░░ ░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
░░░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
░░░░░ ░░░░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
░░░░░░ ░░░░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
░░ ░░░░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░ | ░░░░░░░░░░ |
Opleiding van Ed Mathers Mathers
North Carolina State University | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 9 |
---|---|
NEKTAR THERAPEUTICS | Health Technology |
RHYTHM PHARMACEUTICALS, INC. | Health Technology |
TREVI THERAPEUTICS, INC. | Health Technology |
OBSEVA SA | Health Technology |
RENEO PHARMACEUTICALS, INC. | Health Technology |
INOZYME PHARMA, INC. | Health Technology |
SYNLOGIC, INC. | Health Technology |
MIRUM PHARMACEUTICALS, INC. | Health Technology |
SENTI BIOSCIENCES, INC. | Health Technology |
Bedrijven in privébezit | 37 |
---|---|
MedImmune LLC
MedImmune LLC BiotechnologyHealth Technology MedImmune LLC develops medicines for the prevention and treatment of infectious diseases such as cancer and immune system disorders. It offers solutions in the areas of monoclonal antibodies and vaccines for infection, oncology, respiratory disease and inflammation, cardiovascular diseases, and neuroscience. The company was founded by Wayne T. Hockmeyer in 1988 and is headquartered in Gaithersburg, MD. | Health Technology |
Kémia, Inc.
Kémia, Inc. Pharmaceuticals: MajorHealth Technology Kémia, Inc. discovered and developed novel small molecule therapeutics for inflammation, cancer, HIV, diabetes and bone diseases. The firm specialized in the fields of medicinal and analytical chemistry, biology, pharmacology, pharmacokinetics, pharmacodynamics, and clinical development. The company was founded in 2002 and was headquartered in San Diego, CA. | Health Technology |
Plexxikon, Inc.
Plexxikon, Inc. Miscellaneous Commercial ServicesCommercial Services Plexxikon, Inc. provides clinical and medical drug discovery and development services. The company was founded by Joseph P. Schlessinger, Thomas Richard Kassberg, Sung-hou Kim and K. Peter Hirth in 2001 and is headquartered in Berkeley, CA. | Commercial Services |
MedImmune Ventures, Inc.
MedImmune Ventures, Inc. Investment ManagersFinance MedImmune Ventures, Inc. ( Medimmune Ventures) is a venture capital firm founded in 2002 by Ron Laufer, Wayne Hockmeyer and David Mott . The firm is headquartered in Gaithersburg, Maryland. | Finance |
Satori Pharmaceuticals, Inc.
Satori Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Satori Pharmaceuticals, Inc. developed therapeutics for alzheimer's disease. The firm's drug candidates selectively modulated gamma secretase, the enzyme generating the neurotoxic peptides that form amyloid beta plaques the signature of this debilitated disease. The company was founded by Mark A. Findeis and Dennis J. Selkoe in 2005 and was headquartered in Cambridge, MA. | Health Technology |
Liquidia Technologies, Inc.
Liquidia Technologies, Inc. Pharmaceuticals: MajorHealth Technology Liquidia Technologies, Inc. is a clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT technology to transform the lives of patients. It operates in two segments: Pharmaceutical Products and Partnering & Licensing. The two product candidates from its pipeline: LIQ861 for the treatment of pulmonary arterial hypertension and LIQ865 for the treatment of local post-operative pain. Liquidia Technologies was founded by Joseph M. DeSimone, Ashok K. Mendiratta, Edward T. Samulski, William R. Kenan, Ginger Denison and Jason Rolland in 2004 and is headquartered in Morrisville, NC. | Health Technology |
Biotechnology Innovation Organization
Biotechnology Innovation Organization Miscellaneous Commercial ServicesCommercial Services Biotechnology Innovation Organization is the world's biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. Corporate members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. also represent state and regional biotech associations, service providers to the industry and academic centers. | Commercial Services |
Ra Pharmaceuticals, Inc.
Ra Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Ra Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery and development of peptide-based drugs. It uses Extreme Diversity platform that allows to produce synthetic macrocyclic peptides. The company was founded by James W. Broderick and Douglas A. Treco on June 27, 2008 and is headquartered in Cambridge, MA. | Health Technology |
Lumena Pharmaceuticals, Inc.
Lumena Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Lumena Pharmaceuticals, Inc. developed oral therapeutics for rare liver diseases. The firm was engaged in the development and commercialization of novel products for rare cholestatic liver diseases and serious metabolic disorders, such as nonalcoholic steatohepatitis. The company was founded by Bronislava Gedulin and Michael G. Grey in January 2011 and was headquartered in San Diego, CA. | Health Technology |
Ziarco, Inc. | |
NEA Management Co. LLC
NEA Management Co. LLC Investment ManagersFinance New Enterprise Associates LLC (New Enterprise Associates) is a venture capital firm founded in 1977. The firm headquartered in Menlo Park, California. | Finance |
Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA. | Health Technology |
Southeast BIO | |
North Carolina State University College of Sciences Foundation | |
Glaxo Wellcome, Inc. | Health Technology |
Amplyx Pharmaceuticals, Inc.
Amplyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Amplyx Pharmaceuticals, Inc. develops broad-spectrum antifungal agents for the treatment of life-threatening fungal infections. The firm's compound APX001, shows broad-spectrum activity in animal models of invasive fungal infection by common species of Candida and Aspergillus. It develops oral and injectable anti-infective drugs, including protease inhibitors and antibiotics. The company was founded by André Marquis, Mitchell W. Mutz and Gerry Crabtree in 2006 and is headquartered in San Diego, CA. | Health Technology |
AstraZeneca LP
AstraZeneca LP Pharmaceuticals: MajorHealth Technology Part of AstraZeneca PLC, AstraZeneca LP is a pharmaceutical company that focuses on developing and commercializing prescription drugs for various therapeutic areas. The private company is based in Wilmington, DE. | Health Technology |
Allergan GI Corp.
Allergan GI Corp. BiotechnologyHealth Technology Allergan GI Corp. develops peptide therapeutics for the treatment of gastrointestinal disorders. It provides RM-493 a small-peptide melanocortin-4 receptor agonist, for the treatment of obesity and diabetes, and RM-131 a small-peptide ghrelin agonist, for the treatment of diabetic gastro paresis and other gastrointestinal functional disorders. The company was founded by Bart Henderson and Elizabeth Stoner in 2008 and is headquartered in Madison, NJ. | Health Technology |
Empower Energies Clean Infrastructure LLC
Empower Energies Clean Infrastructure LLC SemiconductorsElectronic Technology Empower Energies, Inc. operates as a full-service renewable energy program manager. It provides customized renewable energy project development, construction, financing and acquisition solutions. The company was founded by Len Jornlin in 2010 and is headquartered in Bethesda, MD. | Electronic Technology |
Lumos Pharma Sub, Inc.
Lumos Pharma Sub, Inc. Medical/Nursing ServicesHealth Services Lumos Pharma Sub, Inc. develops and commercializes a novel treatment for the rare disease creatine transporter deficiency. It focuses on bringing novel therapies to patients afflicted with unmet medical needs in severe, rare, and genetic diseases. The firm's technology LUM-001 is a repurposed small molecule that is a kinetically similar analog of creatine and has shown promising therapeutic potential for the treatment of creatine transporter deficiency. Lumos Pharma was founded by Richard J. Hawkins in 2010 and is headquartered in Austin, TX. | Health Services |
Ziarco Pharma Ltd.
Ziarco Pharma Ltd. BiotechnologyHealth Technology Ziarco Pharma Ltd. provides therapeutics targeting inflammatory and allergic diseases. It focuses on chronic inflammatory skin diseases, atopic dermatitis, and Psoriasis. The company was founded by Michael Yeadon, Wai Leung Liu, Lynn Worth Purkins and Arif Kassam Shivji in 2012 and is headquartered in Sandwich, the United Kingdom. | Health Technology |
Envisia Therapeutics, Inc.
Envisia Therapeutics, Inc. BiotechnologyHealth Technology Envisia Therapeutics, Inc. develops novel ocular therapies. It provides glaucoma drug therapies that include PRINT particle therapeutics to overcome biologic and chemical. The company was founded by 2013 is headquartered in Morrisville, NC. | Health Technology |
Synlogic Operating Co., Inc.
Synlogic Operating Co., Inc. Pharmaceuticals: MajorHealth Technology Synlogic Operating Co., Inc. operates as a biopharmaceutical company. The firm's pipeline focuses on rare diseases, the company is leveraging the broad potential of its synthetic biotics platform for novel drug development in major disease areas through partnerships with pharmaceutical and biotechnology companies. It also engages in development of synthetic biotics-based treatment for inflammatory bowel disease. The company was founded by James J. Collins and Timothy K. Lu in 2014 and is headquartered in Cambridge, MA. | Health Technology |
Ziarco Group Ltd.
Ziarco Group Ltd. Pharmaceuticals: MajorHealth Technology Ziarco Group Ltd. operates as a clinical-stage biotechnology company that develops therapeutics targeting inflammatory skin diseases. The firm engages in development of novel treatments in dermatology. The company was incorporated on March 10, 2014 and is headquartered in Canterbury, the United Kingdom. | Health Technology |
Medimmune, Inc. | Health Technology |
Senti Sub I, Inc.
Senti Sub I, Inc. BiotechnologyHealth Technology Senti Biosciences, Inc. develops novel therapeutics. It specializes in thetic biology, gene therapy and cell therapy. The company was founded by Timothy K. Lu, Wilson Wong, James J. Collins and Philip Lee in 2016 and is headquartered in South San Francisco, CA. | Health Technology |
Akouos, Inc.
Akouos, Inc. BiotechnologyHealth Technology Akouos, Inc. is a precision genetic medicine company, which engages in the development of precision genetic medicines to restore and preserve hearing in genetically-defined patient populations. The firm's lead product candidate, AK-OTOF, is a gene therapy for the treatment of hearing loss due to mutations in the OTOF gene. It develops targeted adeno-associated viral vector based gene therapies for sensorineural hearing loss, which results from dysfunction or damage to sensory cells and nerve fibers of the inner ear. The company was founded by Emmanuel J. Simons, William F. Sewell, Richard H. Smith, Luk H. Vandenberghe, and Michael J. McKenna on March 7, 2016 and is headquartered in Boston, MA. | Health Technology |
SpliceBio SL
SpliceBio SL BiotechnologyHealth Technology SpliceBio SL is a genetic medicines company based in Barcelona, Spain. The Spanish company harnesses its proprietary protein splicing platform to develop the next generation of gene therapies. SpliceBio's platform offers the potential to address diseases that currently cannot be treated with gene therapies because the necessary gene is too large to be delivered by -associated virus (AAV) vectors. The company's lead program targets Stargardt disease, a genetic eye disease that causes vision loss in children and adults. SpliceBio's platform is based on technology developed in the Muir lab at Princeton University after more than 20 years of pioneering intein and protein engineering research. The company was founded by Dominguez Silvia Frutos, Miquel Vila-Perelló, and Miquel Vila-Perelló has been the CEO since incorporation. | Health Technology |
Inversago Pharma, Inc.
Inversago Pharma, Inc. Pharmaceuticals: MajorHealth Technology Inversago Pharma, Inc. develops novel gastrointestinal drugs. The company was founded by Fran?ois Ravenelle in and is headquartered in Montreal, Canada. | Health Technology |
Shape Therapeutics, Inc.
Shape Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Shape Therapeutics, Inc. operates as a biotechnology firm. It offers genome medicine. The company was founded by Francois Vigneault and John D. Suliman in 2018 and is headquartered in Seattle, WA. | Health Technology |
MBX Biosciences, Inc.
MBX Biosciences, Inc. Electronic Equipment/InstrumentsElectronic Technology MBX Biosciences, Inc. operates as a preclinical-stage biotech company. It creates therapies to treat rare endocrine diseases. The company was founded by Peter Kent Hawryluk and Timothy Knickerbocker and is headquartered in Carmel, IN. | Electronic Technology |
Curzion Pharmaceuticals, Inc.
Curzion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Curzion Pharmaceuticals, Inc. operates as a pharmaceutical firm. The company is headquartered in San Diego, CA. | Health Technology |
Affinia Therapeutics, Inc.
Affinia Therapeutics, Inc. BiotechnologyHealth Technology Affinia Therapeutics, Inc. is a preclinical stage company, which engages in the research and development of gene therapy. It offers Affinia Rationally-designed Therapies (ART) platform, which develops novel therapies, focusing on the key components of a gene therapy: capsids, which are the outer shells of a virus used to package the genetic code to treat a disease; promoters, which control how the cells read the genetic code that is delivered; and manufacturing approaches, which determine the quality and cost of potential medicines. The company was founded by Luk Vandenberghe, Botond Roska, and Aaron Tward in 2019 and is headquartered in Waltham, MA. | Health Technology |
Code Biotherapeutics, Inc.
Code Biotherapeutics, Inc. BiotechnologyHealth Technology Code Biotherapeutics, Inc. is a next-generation gene therapy company based in Greater Philadelphia. The American company is focused on developing targeted non-viral gene therapies to treat serious and life-threatening genetic diseases. The company uses a novel multivalent synthetic DNA delivery platform called 3DNA, which overcomes many of the challenges associated with viral-based gene therapies. Code Biotherapeutics is advancing an internal pipeline focused on select rare disease programs and establishing partnerships to take forward programs in both rare and prevalent diseases. Code Biotherapeutics is supported by top-tier investors that believe in their work to drive discovery programs forward as they aim to deliver on the promise of their proprietary synthetic DNA-based, non-viral genetic medicines delivery platform. The company was founded by Brian P. McVeigh, who has been the CEO since incorporation. | Health Technology |
Sorriso Pharmaceuticals, Inc.
Sorriso Pharmaceuticals, Inc. BiotechnologyHealth Technology Sorriso Pharmaceuticals, Inc. is an American biotechnology company that focuses on developing disease-modifying antibodies to treat inflammatory diseases. Sorriso Pharmaceuticals was founded by Ciara Kennedy, who has been the CEO since its incorporation. | Health Technology |
New Enterprise Associates, Inc. | |
Mirna Therapeutics, Inc.
Mirna Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Mirna Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of microRNA-based oncology therapeutics. Its products includes miR-34, miR-215, miR-101, miR-16, and let-7. The company was founded Matthew M. Winkler in 2007 and is headquartered in Austin, TX. | Commercial Services |